Anthony D'adamio Sells 4,380 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bioventus Trading Up 0.6 %

NYSE:BVS traded up $0.06 on Friday, reaching $10.01. 427,919 shares of the company's stock were exchanged, compared to its average volume of 219,538. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The firm has a market capitalization of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85. The business has a fifty day moving average of $10.32 and a 200-day moving average of $10.85. Bioventus Inc. has a 52-week low of $3.90 and a 52-week high of $14.38.

Analyst Upgrades and Downgrades

BVS has been the topic of several recent research reports. Canaccord Genuity Group boosted their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and boosted their price objective for the company from $12.00 to $13.00 in a report on Tuesday, December 17th.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Bioventus by 38.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company's stock worth $4,662,000 after buying an additional 109,359 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Bioventus in the third quarter valued at approximately $4,515,000. Point72 Asset Management L.P. acquired a new position in Bioventus in the third quarter valued at approximately $788,000. JPMorgan Chase & Co. boosted its holdings in Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after purchasing an additional 176,442 shares in the last quarter. Finally, State Street Corp boosted its holdings in Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company's stock valued at $8,084,000 after purchasing an additional 189,216 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.